Impaired neurovascular coupling in the APPxPS1 mouse model of Alzheimer's disease

Current Alzheimer Research

Volumn 9, Issue 10, 2012, Pages 1221-1230

  Rancillac, Armelle ^a   Geoffroy, Hélène ^a   Rossier, Jean ^a  

^a Brain Plasticity Unit   (France)

Author keywords

Blood vessels; DMPP; Interneurons; Neuropeptide Y; Nicotinic cholinergic receptors; Nitric oxide; Somatosensory cortex; U46619

Indexed keywords

1,1 DIMETHYL 4 PHENYLPIPERAZINIUM; 15 HYDROXY 11ALPHA,9ALPHA EPOXYMETHANOPROSTA 5,13 DIENOIC ACID; NEUROPEPTIDE Y; NICOTINIC RECEPTOR; NITRIC OXIDE;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASTROCYTE; BLOOD VESSEL PARAMETERS; BLOOD VESSEL REACTIVITY; BRAIN BLOOD FLOW; BRAIN SLICE; CONTROLLED STUDY; INTERNEURON; MALE; MICROSCOPY; MOUSE; NEOCORTEX; NERVE CELL; NEUROVASCULAR COUPLING; NONHUMAN; PRIORITY JOURNAL; SOMATOSENSORY CORTEX; VASOCONSTRICTION; VASODILATATION; VASOMOTOR REFLEX; WILD TYPE;

15-HYDROXY-11 ALPHA,9 ALPHA-(EPOXYMETHANO)PROSTA-5,13-DIENOIC ACID; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; AMYLOID BETA-PROTEIN PRECURSOR; ANIMALS; AREA UNDER CURVE; BLOOD VESSELS; BRAIN; CEREBROVASCULAR CIRCULATION; DIMETHYLPHENYLPIPERAZINIUM IODIDE; DISEASE MODELS, ANIMAL; GANGLIONIC STIMULANTS; HUMANS; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; MUTATION; NEUROPEPTIDE Y; PRESENILIN-1; VASOCONSTRICTOR AGENTS; VASODILATION;

EID: 84865080225     PISSN: 15672050     EISSN: 18755828     Source Type: Journal    
DOI: 10.2174/156720512804142859     Document Type: Article

References (69)

1. Selkoe DJ. Alzheimer's disease is a synaptic failure. Science 298(5594): 789-791 (2002).
2. Morrison JH, Hof PR. Selective vulnerability of corticocortical and hippocampal circuits in aging and Alzheimer's disease. Prog Brain Res 13 6467-486 (2002).
3. Palop JJ, Chin J, Roberson ED, Wang J, Thwin MT, Bien-Ly N, et al. Aberrant excitatory neuronal activity and compensatory remodeling of inhibitory hippocampal circuits in mouse models of Alzheimer's disease. Neuron 55(5): 697-711 (2007).
4. Iadecola C. Neurovascular regulation in the normal brain and in Alzheimer's disease. Nat Rev Neurosci 5(5): 347-360 (2004).
5. Cauli B, Hamel E. Revisiting the role of neurons in neurovascular coupling. Front Neuroenergetics 29. (2010).
6. Lecrux C, Hamel E. The neurovascular unit in brain function and disease. Acta Physiol (Oxf) 203(1): 47-59 (2011).
7. Hock C, Villringer K, Muller-Spahn F, Wenzel R, Heekeren H, Schuh-Hofer S, et al. Decrease in parietal cerebral hemoglobin oxygenation during performance of a verbal fluency task in patients with Alzheimer's disease monitored by means of near-infrared spectroscopy (NIRS)--correlation with simultaneous rCBF-PET measurements. Brain Res 755(2): 293-303 (1997).
8. Mentis MJ, Alexander GE, Krasuski J, Pietrini P, Furey ML, Schapiro MB, et al. Increasing required neural response to expose abnormal brain function in mild versus moderate or severe Alzheimer's disease: PET study using parametric visual stimulation. Am J Psychiatry 155(6): 785-794 (1998).
9. Rombouts SA, Barkhof F, Veltman DJ, Machielsen WC, Witter MP, Bierlaagh MA, et al. Functional MR imaging in Alzheimer's disease during memory encoding. AJNR Am J Neuroradiol 21(10): 1869-1875 (2000).
10. Zlokovic BV. Neurovascular pathways to neurodegeneration in Alzheimer's disease and other disorders. Nat Rev Neurosci 12(12): 723-738 (2011).
11. Hamel E, Nicolakakis N, Aboulkassim T, Ongali B, Tong XK. Oxidative stress and cerebrovascular dysfunction in mouse models of Alzheimer's disease. Exp Physiol 93(1): 116-120 (2008).
12. Iadecola C, Zhang F, Niwa K, Eckman C, Turner SK, Fischer E, et al. SOD1 rescues cerebral endothelial dysfunction in mice overexpressing amyloid precursor protein. Nat Neurosci 2(2): 157-161 (1999).
13. Nicolakakis N, Hamel E. Neurovascular function in Alzheimer's disease patients and experimental models. J Cereb Blood Flow Metab (2011).
14. Shi J, Perry G, Smith MA, Friedland RP. Vascular abnormalities: the insidious pathogenesis of Alzheimer's disease. Neurobiol Aging 21(2): 357-361 (2000).
15. Brown WR, Thore CR. Review: Cerebral microvascular pathology in aging and neurodegeneration. Neuropathol Appl Neurobiol (2010).
16. de la Torre JC. Vascular basis of Alzheimer's pathogenesis. Ann N Y Acad Sci 977196-215 (2002).
17. Zlokovic BV. Neurovascular mechanisms of Alzheimer's neurodegeneration. Trends Neurosci 28(4): 202-208 (2005).
18. Benarroch E. Neurovascular unit dysfunction: A vascular component of Alzheimer disease? Neurology 68(May 15): 1730-1732 (2007).
19. Blanchard V, Moussaoui S, Czech C, Touchet N, Bonici B, Planche M, et al. Time sequence of maturation of dystrophic neurites associated with Abeta deposits in APP/PS1 transgenic mice. Exp Neurol 184(1): 247-263 (2003).
20. Narumiya S, Hirata N, Namba T, Hayashi Y, Ushikubi F, Sugimoto Y, et al. Structure and function of prostanoid receptors. J Lipid Mediat 6(1-3): 155-161 (1993).
21. Cauli B, Tong XK, Rancillac A, Serluca N, Lambolez B, Rossier J, et al. Cortical GABA interneurons in neurovascular coupling: relays for subcortical vasoactive pathways. J Neurosci 24(41): 8940-8949 (2004).
22. Rancillac A, Rossier J, Guille M, Tong XK, Geoffroy H, Amatore C, et al. Glutamatergic Control of Microvascular Tone by Distinct GABA Neurons in the Cerebellum. J Neurosci 26(26): 6997-7006 (2006).
23. Porter JT, Cauli B, Tsuzuki K Lambolez B, Rossier J, Audinat E. Selective excitation of subtypes of neocortical interneurons by nicotinic receptors. J Neurosci 19(13): 5228-5235 (1999).
24. Xiang Z, Huguenard JR, Prince DA. Cholinergic switching within neocortical inhibitory networks. Science 281(5379): 985-988 (1998).
25. Gulledge AT, Park SB, Kawaguchi Y, Stuart GJ. Heterogeneity of phasic cholinergic signaling in neocortical neurons. J Neurophysiol 97(3): 2215-2229 (2007).
26. Wilcock DM, Gordon MN, Morgan D. Quantification of cerebral amyloid angiopathy and parenchymal amyloid plaques with Congo red histochemical stain. Nat Protoc 1(3): 1591-1595 (2006).
27. Nishimura N, Schaffer CB, Friedman B, Lyden PD, Kleinfeld D. Penetrating arterioles are a bottleneck in the perfusion of neocortex. Proc Natl Acad Sci USA 104(1): 365-370 (2007).
28. Lee S, Hjerling-Leffler J, Zagha E, Fishell G, Rudy B. The largest group of superficial neocortical GABAergic interneurons expresses ionotropic serotonin receptors. J Neurosci 30(50): 16796-16808 (2010).
29. Perrenoud Q, Rossier J, Férézou I, Geoffroy H, Gallopin T, Vitalis T, Rancillac A.Activation of cortical 5-HT(3) receptor-expressing interneurons induces NO mediated vasodilatations and NPY mediated vasoconstrictions. Front Neural Circuits. 2012;6:50. Epub 2012 Aug 10.
30. Abounader R, Elhusseiny A, Cohen Z, Olivier A, Stanimirovic D, Quirion R, et al. Expression of neuropeptide Y receptors mRNA and protein in human brain vessels and cerebromicrovascular cells in culture. J Cereb Blood Flow Metab 19(2): 155-163 (1999).
31. Li J, Wang YJ, Zhang M, Gao CY, Fang CQ, Yan JC, et al. Vascular risk factors promote conversion from mild cognitive impairment to Alzheimer disease. Neurology 76(17): 1485-1491 (2011).
32. Yang DS, Kumar A, Stavrides P, Peterson J, Peterhoff CM, Pawlik M, et al. Neuronal apoptosis and autophagy cross talk in aging PS/APP mice, a model of Alzheimer's disease. Am J Pathol 173(3): 665-681 (2008).
33. Cook DG, Forman MS, Sung JC, Leight S, Kolson DL, Iwatsubo T, et al. Alzheimer's A beta(1-42) is generated in the endoplasmic reticulum/intermediate compartment of NT2N cells. Nat Med 3(9): 1021-1023 (1997).
34. Hartmann T, Bieger SC, Bruhl B, Tienari PJ, Ida N, Allsop D, et al. Distinct sites of intracellular production for Alzheimer's disease A beta40/42 amyloid peptides. Nat Med 3(9): 1016-1020 (1997).
35. Xu H, Sweeney D, Wang R, Thinakaran G, Lo AC, Sisodia SS, et al. Generation of Alzheimer beta-amyloid protein in the trans-Golgi network in the apparent absence of vesicle formation. Proc Natl Acad Sci USA 94(8): 3748-3752 (1997).
36. Greenfield JP, Tsai J, Gouras GK, Hai B, Thinakaran G, Checler F, et al. Endoplasmic reticulum and trans-Golgi network generate distinct populations of Alzheimer beta-amyloid peptides. Proc Natl Acad Sci USA 96(2): 742-747 (1999).
37. Langui D, Girardot N, El Hachimi KH and others. Subcellular topography of neuronal Abeta peptide in APPxPS1 transgenic mice. Am J Pathol 165(5): 1465-1477 (2004).
38. Schmitz C, Rutten BP, Pielen A and others. Hippocampal neuron loss exceeds amyloid plaque load in a transgenic mouse model of Alzheimer's disease. Am J Pathol 164(4): 1495-1502 (2004).
39. Moreno-Gonzalez I, Baglietto-Vargas D, Sanchez-Varo R and others. Extracellular amyloid-beta and cytotoxic glial activation induce significant entorhinal neuron loss in young PS1(M146L)/APP(751SL) mice. J Alzheimers Dis 18(4): 755-776 (2009).
40. Nixon RA, Wegiel J, Kumar A and others. Extensive involvement of autophagy in Alzheimer disease: an immuno-electron microscopy study. J Neuropathol Exp Neurol 64(2): 113-122 (2005).
41. Yu WH, Cuervo AM, Kumar A and others. Macroautophagy--a novel Beta-amyloid peptide-generating pathway activated in Alzheimer's disease. J Cell Biol 171(1): 87-98 (2005).
42. Wirths O, Weis J, Szczygielski J, Multhaup G, Bayer TA. Axonopathy in an APP/PS1 transgenic mouse model of Alzheimer's disease. Acta Neuropathol 111(4): 312-319 (2006).
43. Niwa K, Younkin L, Ebeling C and others. Abeta 1-40-related reduction in functional hyperemia in mouse neocortex during somatosensory activation. Proc Natl Acad Sci USA 97(17): 9735-9740 (2000).
44. Christie R, Yamada M, Moskowitz M, Hyman B. Structural and functional disruption of vascular smooth muscle cells in a transgenic mouse model of amyloid angiopathy. Am J Pathol 158(3): 1065-1071 (2001).
45. Niwa K, Kazama K, Younkin SG, Carlson GA, Iadecola C. Alterations in cerebral blood flow and glucose utilization in mice overexpressing the amyloid precursor protein. Neurobiol Dis 9(1): 61-68 (2002).
46. El Tayara NT, Delatour B, Volk A, Dhenain M. Detection of vascular alterations by in vivo magnetic resonance angiography and histology in APP/PS1 mouse model of Alzheimer's disease. MAGMA 23(1): 53-64 (2010).
47. de la Torre JC, Mussivand T. Can disturbed brain microcirculation cause Alzheimer's disease? Neurol Res 15(3): 146-153 (1993).
48. Ramos B, Baglietto-Vargas D, del Rio JC and others. Early neuropathology of somatostatin/NPY GABAergic cells in the hippocampus of a PS1xAPP transgenic model of Alzheimer's disease. Neurobiol Aging 27(11): 1658-1672 (2006).
49. Whitehouse PJ, Au KS. Cholinergic receptors in aging and Alzheimer's disease. Prog Neuropsychopharmacol Biol Psychiatry 10(3-5): 665-676 (1986).
50. James JR, Nordberg A. Genetic and environmental aspects of the role of nicotinic receptors in neurodegenerative disorders: emphasis on Alzheimer's disease and Parkinson's disease. Behav Genet 25(2): 149-159 (1995).
51. Abounader R, Villemure JG, Hamel E. Characterization of neuropeptide Y (NPY) receptors in human cerebral arteries with selective agonists and the new Y1 antagonist BIBP 3226. Br J Pharmacol 116(4): 2245-2250 (1995).
52. Dacey RG, Jr., Bassett JE, Takayasu M. Vasomotor responses of rat intracerebral arterioles to vasoactive intestinal peptide, substance P, neuropeptide Y, and bradykinin. J Cereb Blood Flow Metab 8(2): 254-261 (1988).
53. Yang G, Chen G, Ebner TJ, Iadecola C. Nitric oxide is the predominant mediator of cerebellar hyperemia during somatosensory activation in rats. Am J Physiol 277(6 Pt 2): R1760-R1770 (1999).
54. Yang G, Huard JM, Beitz AJ, Ross ME, Iadecola C. Stellate neurons mediate functional hyperemia in the cerebellar molecular layer. J Neurosci 20(18): 6968-6973 (2000).
55. Brown LA, Key BJ, Lovick TA. Fluorescent imaging of nitric oxide production in neuronal varicosities associated with intraparenchymal arterioles in rat hippocampal slices. Neurosci Lett 294(1): 9-12 (2000).
56. Lovick TA, Brown LA, Key BJ. Neurovascular relationships in hippocampal slices: physiological and anatomical studies of mechanisms underlying flow-metabolism coupling in intraparenchymal microvessels. Neuroscience 92(1): 47-60 (1999).
57. Estrada C, DeFelipe J. Nitric oxide-producing neurons in the neocortex: morphological and functional relationship with intraparenchymal microvasculature. Cereb Cortex 8(3): 193-203 (1998).
58. Tong XK, Hamel E. Basal forebrain nitric oxide synthase (NOS)-containing neurons project to microvessels and NOS neurons in the rat neocortex: cellular basis for cortical blood flow regulation. Eur J Neurosci 12(8): 2769-2780 (2000).
59. Liu X, Li C, Falck JR and others. Interaction of nitric oxide, 20-HETE, and EETs during functional hyperemia in whisker barrel cortex. Am J Physiol Heart Circ Physiol 295(2): H619-H631 (2008).
60. Pogun S, Demirgoren S, Taskiran D and others. Nicotine modulates nitric oxide in rat brain. Eur Neuropsychopharmacol 10(6): 463-472 (2000).
61. Petzold GC, Murthy VN. Role of astrocytes in neurovascular coupling. Neuron 71(5): 782-797 (2011).
62. Garthwaite J, Boulton CL. Nitric oxide signaling in the central nervous system. Annu Rev Physiol 57683-706 (1995).
63. Jaffrey SR, Snyder SH. Nitric oxide: a neural messenger. Annu Rev Cell Dev Biol 11417-440 (1995).
64. Fleming I. Cytochrome p450 and vascular homeostasis. Circ Res 89(9): 753-762 (2001).
65. Fujimoto Y, Uno E, Sakuma S. Effects of reactive oxygen and nitrogen species on cyclooxygenase-1 and -2 activities. Prostaglandins Leukot Essent Fatty Acids 71(5): 335-340 (2004).
66. Salvemini D. Regulation of cyclooxygenase enzymes by nitric oxide. Cell Mol Life Sci 53(7): 576-582 (1997).
67. Willmott NJ, Wong K, Strong AJ. A fundamental role for the nitric oxide-G-kinase signaling pathway in mediating intercellular Ca(2+) waves in glia. J Neurosci 20(5): 1767-1779 (2000).
68. Calcinaghi N, Jolivet R, Wyss MT and others. Metabotropic glutamate receptor mGluR5 is not involved in the early hemodynamic response. J Cereb Blood Flow Metab 31(9): e1-10 (2011).
69. Wang X, Lou N, Xu Q and others. Astrocytic Ca2+ signaling evoked by sensory stimulation in vivo. Nat Neurosci 9(6): 816-823 (2006).